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Abstract
Background: Smoking cessation has important immediate health benefits. The comparative short-
term effectiveness of smoking cessation interventions is not well known. We aimed to determine
the relative effectiveness of nicotine replacement therapy (NRT), bupropion and varenicline at 4
weeks post-target quit date.
Methods: We searched 10 electronic medical databases (inception to October 2008). We
selected randomized clinical trials [RCTs] evaluating interventions for our primary outcome of
abstinence from smoking at at-least 4 weeks post-target quit date, with biochemical confirmation.
We conducted random-effects odds ratio (OR) meta-analysis and meta-regression. We compared
treatment effects across interventions using head-to-head trials and calculated indirect
comparisons.
Results: We combined a total of 101 trials evaluating delivery of NRT versus inert controls at
approximately 4 weeks post-target quit date (total n = 31,321). The pooled overall OR is OR 2.05
(95% Confidence Interval [CI], 1.89-2.23, P =< 0.0001). We pooled data from 31 bupropion trials
contributing a total n of 11,118 participants and found a pooled OR of 2.25 (95% CI, 1.94-2.62, P
=< 0.0001). We evaluated 9 varenicline trials compared to placebo. Our pooled estimate for
cessation at 4 weeks post-target quit date found a pooled OR of 3.16 (95% CI, 2.55-3.91, P =<
0.0001). Two trials evaluated head to head comparisons of varenicline and bupropion and found a
pooled estimate of OR 1.86 (95% CI, 1.49-2.33, P =< 0.0001 at 4 weeks post-target quit date.
Indirect comparisons were: NRT and bupropion, OR, 1.09, 95% CI, 0.93-1.31, P = 0.28; varenicline
and NRT, OR 1.56, 95% CI, 1.23-1.96, P = 0.0002; and, varenicline and bupropion, OR 1.40, 95%
CI, 1.08-1.85, P = 0.01.
Conclusion: Pharmacotherapeutic interventions are effective for increasing smoking abstinence
rates in the short-term.
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Smoking remains the leading cause of preventable death
in the world.[1] Smoking cessation is associated with
important benefits at the individual and societal levels.
Given the prevalence of smoking, considerable efforts
have been directed toward developing interventions to
assist smokers in quitting. However, smoking cessation
interventions have had heterogeneous successes.[2]
Smoking cessation is necessary to reduce future morbidity
and mortality, however many patients have difficulty dis-
continuing.
Both psychosocial and pharmaceutical interventions have
been evaluated for their success in achieving smoking dis-
continuation.[3,4] Drug therapies are now licensed in
North America and Europe to promote smoking cessa-
tion. The most commonly evaluated of these has been nic-
otine replacement therapy [NRT].[5,6] More recently,
attention has focused on the use of anti-depressant ther-
apy and specifically the agent bupropion[7]. A new inter-
vention approved in 2006, varenicline, targets nicotine
receptors to reduce craving and pleasure sensations.
Recent guidelines and evaluations call for combining ther-
apies to provide optimal patient management.[3,8]
We,.[9] and others,. [10-13] have previously reported on
the efficacy of these interventions for longer-term cessa-
tion (3-12 months) durations. No systematic review has
yet evaluated short-term quit rates from available thera-
pies. Guidelines for smoking cessation programmes con-
sider quitting 4-weeks post-planned quit date as a
successful short-term cessation.[14] Short-term smoking
abstinence is especially important in patients requiring
immediate behaviour changes, such as those with recent
cardiovascular events.[15] or undergoing surgery.[16] We
conducted a meta-analysis of Randomized Clinical Trials
[RCTs] to identify the effectiveness of the various pharma-
cological interventions in improving abstinence rates at 4-
weeks and 6 months.
Methods
Eligibility Criteria
Our primary outcome of interest was smoking abstinence
at approximately 4 weeks post-target quit date (TQD).
Our secondary outcomes were short-term smoking absti-
nence defined as 6 months after initiating treatment or
closest available data to that time point, within one
month. We included any RCT of NRT of any delivery
method, bupropion or varenicline. We included only
RCTs of at least 4 weeks duration with biochemical confir-
mation of smoking abstinence because of the likelihood
of abstinence over-reporting. While methods of assessing
smoking abstinence vary from study to study, the most
common method is self-report. However, this can have
false cessation rates as high as 30%.[17]False reporting is
most likely to occur in a trial setting or in assessing smok-
ing status after a medical event. Laboratory tests are often
used to verify smoking status, especially in clinical trials.
Methods of biological verification include serum and
saliva thiocyanate (SCN), expired carbon monoxide
(CO), plasma, saliva and urinary cotinine and plasma and
urinary nicotine. Each of these have various strengths and
weaknesses.[18] Studies had to report smoking abstinence
as either sustained abstinence at the time periods or point-
prevalence of abstinence. When both outcomes were
available, we considered sustained abstinence to be a
superior clinical marker of abstinence. We excluded dose
ranging studies, non-RCTs, post-hoc analyses, mainte-
nance therapy, and studies that reported outcomes as self-
report.
Study endpoints
Our primary endpoint was the 4-week post-TQD. This is
variably reported in studies over years of publications.
National committees require data on the 4-week post-
TQD and each group of trials of intervention deals with
this endpoint differently. Newer studies typically report
this as the last 4-weeks of treatment as pharmacotherapy
is begun prior to TQD. Where this specific endpoint is
reported, we extracted data on 4-week post-TQD. Where
not reported, we extracted data on 4 weeks post-interven-
tion. Our secondary endpoint, 6-months post interven-
tion is typically reported as 6 months post-treatment, but
may also be reported as 6 months post TQD. Where
reported specifically, we extracted data on 6-month post-
TQD.
Search strategy
In consultation with a medical librarian (PR), we estab-
lished a search strategy. We searched independently, in
duplicate, the following 10 databases (from inception to
October 1, 2008): MEDLINE, EMBASE, Cochrane CEN-
TRAL, AMED, CINAHL, TOXNET, Development and
Reproductive Toxicology, Hazardous Substances Data-
bank, Psych-info and Web of Science, databases that
included the full text of journals (OVID, ScienceDirect, and
Ingenta, including articles in full text from approximately
1700 journals since 1993). In addition, we searched the
bibliographies of published systematic reviews.[5,19-
25,7,10,11,13,26] and health technology assess-
ments.[27] Searches were not limited by language, sex or
age.
Study selection
Two investigators (EM, PW) working independently, in
duplicate, scanned all abstracts and obtained the full text
reports of records, that indicated or suggested that the
study was a RCT evaluating a smoking abstinence therapy
on the outcomes of interest. After obtaining full reports of
the candidate trials (either in full peer-reviewed publica-Page 2 of 16
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assessed eligibility from full text papers.
Data collection
Two reviewers (PW, EM) conducted data extraction inde-
pendently using a standardized pre-piloted form. Review-
ers collected information about the smoking intervention
tested, the population studied (age, sex, underlying condi-
tions), treatment dosages and dosing schedules, the treat-
ment effect at 4 weeks post-TQD and at 6 months post-
intervention, the specific measurement of abstinence (sus-
tained or point-prevalence), and the chemical confirma-
tion methods. Study evaluation included general
methodological quality features including allocation con-
cealment, sequence generation, blinding status, intention-
to-treat, and appropriate descriptions of loss to follow-up.
We entered the data into an electronic database such that
duplicate entries existed for each study; when the two
entries did not match, we resolved differences through
discussion and consensus.
Data analysis
In order to assess inter-rater reliability on inclusion of arti-
cles, we calculated the Phi statistic, which provides a meas-
ure of inter-observer agreement independent of
chance.[28] We calculated the Odds Ratios [OR] and
appropriate 95% Confidence Intervals [CIs] of outcomes
according to the number of events of abstinence reported
in the original studies or sub-studies. Odds Ratios are the
preferred effect measure in smoking cessation trials. In cir-
cumstances of zero outcome events in one arm of a trial,
we added 1 to each arm, as suggested by Sheehe.[29] We
first pooled studies of all NRT interventions versus all con-
trols using the DerSimonian-Laird random effects
method,.[30] which recognizes and anchors studies as a
sample of all potential studies, and incorporates an addi-
tional between-study component to the estimate of varia-
bility.[31] We calculated the I2 statistic for each analysis as
a measure of the proportion of the overall variation that is
attributable to between-study heterogeneity.[32] Forest
plots are displayed for each primary analysis, showing
individual study effect measures with 95% CIs, and the
overall DerSimmonian-Laird pooled estimate. We then
conducted a meta-regression analysis on the NRT studies
with predictors of heterogeneity including the following
covariates: placebo control; reporting of sequence genera-
tion; reporting of allocation concealment; use of gum or
patch; and, method of chemical confirmation of absti-
nence. We additionally conducted separate pooled analy-
ses of NRT versus placebo, gum versus control and patch
versus control. We conducted all analyses at 4 weeks and
also at 6 months post-TQD. For bupropion trials, we
pooled all bupropion trials versus all controls and con-
ducted a meta-regression analysis using the following cov-
ariates: placebo control; reporting of sequence generation;
reporting of allocation concealment; method of chemical
confirmation of abstinence; and plans to quit. We con-
ducted separate meta-regression analyses and calculated
the relevant ORs for the covariates as the exponent of the
coefficient.[33] We additionally pooled all placebo-con-
trolled trials and evaluated effect sizes at 4 weeks and at 6
months post-TQD. For head-to-head trials of bupropion
versus NRT, we conducted pooled random-effects analy-
ses at 4 weeks and at 6 months post-TQD. For varenicline
trials, we conducted pooled random-effects analyses of
varenicline versus placebo and for head-to-head trials of
varenicline versus bupropion or NRT at 4 weeks year and
at 6 months. post-TQD. Head-to-head trials provide the
strongest inferences regarding intervention superior-
ity.[34] However, with so few head-to-head trials of varen-
icline versus NRT, we conducted indirect comparisons of
these interventions versus placebo using methods
described by Bucher et al.[35] This method maintains the
randomization from each trial and compares the sum-
mary estimates of pooled interventions with CIs. Analyses
were conducted using StatsDirect (version 2.5.2, http://
www.statsdirect.com) and Comprehensive Meta-analysis
(version 2, http://www.meta-analysis.com).
Results
Study inclusion
We identified 795 abstracts from our extensive searches.
We excluded 532 as irrelevant to meeting our inclusion
criteria. We obtained 263 full-text studies for screening.
We further excluded 94 studies for reasons explained in
figure 1 [See Additional File 1]. In total, we included data
from 168 RCTs. Agreement was near perfect (φ => 0.9).
Methods reporting
Nicotine Replacement Therapy
One hundred and fifteen RCTs of NRT provided either safety
or efficacy data at approximately 4 weeks post-TQD. [36-
150]. Eighty-two (82/115) used a placebo control [36-
116,150]. Trials were variably reported with only 43 report-
ing methods of sequence generation[37,39,41,46, 52,55,
57,70,73-76,80,83,85-92,95-98,103,105,110-112, 114-
116, 118,121,125,126,139,142,144,145,148]. Eighteen
(18/115) reported on allocation concealment. [37,39,
41,46,70,76,81,84,86,88-90,95, 105,111,112,126,148],
81 (81/115) reported on who was blinded   [36-73,
75-78,120,131,132,79-94,96-98,149,100-103,105-116].
Most trials used some form of chemical confirmation of
abstinence, with carbon monoxide being the most common
(104/115).[36-38,40-57,59-71,73,117-120,122-124, 129-
134].[72,74-81,83-94,97-99,135,137-140,149, 100-111,
113-116,141-148], salivary cotinine (26/115).
[42,45,46,50, 56,66,68,75,76,79,83,93,95, 103,
106,111,123,125, 128, 129,132-134,145,147,150], serumPage 3 of 16
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Flow diagram of included studiesigure 1
Flow diagram of included studies.
o 474 abstract screened for inclusion after searching with 
“nicotine” AND “smoking” AND “gum OR Patch 
OR spray OR inhalers OR Tablet OR lozenge” AND 
“random*”
o 280 abstacts were obtained when using “bupropion”
and “smoking” and “random” and “clinical trial”
o 41 abstracts were obtained when using “varenicline”
and “random” and “clinical trial”
o 532 abstracts excluded as irrelevant
o 167 NRT- relevant full-text paper publications retrieved 
for potential inclusion
o 80 bupropion-relevant full-text-paper were obtained 
for potential further review
o 16 varencline-relevant full-text papers were obtained 
for potential further review
52 NRT relevant studies were further excluded:
 15: duplicated studies
 12: intervention not comparable or NRT can’t be 
independently evaluated
 5: only with one-year abstinence data and no side 
effect reported
 2: smoking reduction studies 
 4: smoking abstinence and craving studies
 12: not NRT side effect and abstinence related studies
 1: genotype and NRT response
38 bupropion-relevant studies were further excluded:
 5: Bupropion can’t be independently evaluated
 4: comparison of different dosage
 11:duplicate studies
 16:not abstinence or bupropion side effects related
 2: not RCT
5 varenicline-relevant studies were further excluded for the 
following reason
 4:without abstinence data 
 1: varenicline vs other treatment
115 NRT studies included in analysis.
 101 in 4-week efficacy analysis
 All compare NRT with placebo or no NRT 
independently.
42 bupropion studies included in the analysis
 40 studies compare bupropion with placebo
 2 studies compare bupropion with education 
or no Tx.
 31 trials in 4-week efficacy analysis
11 studies included in the analysis
 All 11 in 4 week efficacy analysis
 10 studies compare varenicline with placebo
 1 compares varenicline with NRT
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pling (4/115)[74,112,126,129]. Most (94/115) reported
that participants were trying to quit smoking.[36-39,41,44-
52,54-65,117,118,121,122,124-129,131, 132, 68-
75,77,78,80-82,85-87,89-91,93,94,97-100,102-
106,108,110-116,136-140,143-149].
Bupropion
Forty-two bupropion trials met our inclusion crite-
ria.[113,114,142,143,149,151-187] and reported on out-
comes at 4 weeks post-TQD. Almost all trials (40/42) used
a placebo control.[113,114,149,151-187], with 2 provid-
ing education.[143] and counseling.[142] as controls. The
quality of reporting studies varied considerably. We found
that important study quality indicators were reported spo-
radically. Sequence generation was reported in 23 of 42
trials.[113,114,142,152-154,157-159,161-164,169-173,
176,180,182,185,186], allocation concealment was
reported in 12 of 42 trials.[152,153,157-159,162-
164,170,176,182,186], the status of who was blinded was
reported in 38 of 42 trials.[113,114,142,149,151-
174,176,177,180-187], 37 trials.[113,114,142,143, 149,
151-155,157-165,167-172,174-177,180-187] confirmed
cessation using carbon monoxide testing, while 13 used
urinary cotinine[114,152,153,157-159,166,173,174,178-
180,184]. Almost all trials used participants that were
planning to quit smoking (38/42).[113,114,142, 143,
149,151-161,163,165-171,173-180,182-187].
Varenicline
Eleven varenicline studies met our inclusion criteria[162-
164,188-195]. One reported only on safety[193]. All trials
had a placebo control, 3 also had a bupropion control in
their 3 armed trials[163,164,188]. We found that almost
all (7/11) provided an additional intervention of coun-
seling available[162-164,190-192,194]. Sequence genera-
tion was reported in 6 of 11 studies.[162-164,189,
192,195], allocation concealment in 7 of 11 studies.[162-
164,189,192,194,195], blinding status in all studies (11/
11), and the use of carbon monoxide testing in 10 of 11
studies.[162-164,188-192,194,195], and urinary cotinine
in 1 of 11 studies[193]. Five trials reported that the partic-
ipants were trying to stop smoking[163,189,
190,192,195].
Effectiveness
Nicotine Replacement Therapy
We combined a total of 101 trials.[36-43,45-47,49-52,54-
65,117-119,121,123,128-132,147].[66-69,71,73-82,84
,86-90,134,135,137,138,149,91,94,95,97-100,103,105,
106,111,114-116,139-146]evaluating some delivery form
of NRT versus inert controls at approximately 4 weeks
post-TQD (total n = 31,321). The pooled overall OR is OR
2.05 (95% CI, 1.89-2.23, P =< 0.0001, I2 = 51.8%, 95% CI
= 38% to 61.3%, P =< 0.0001, See Figure 2). This assess-
ment permitted a sufficient number of studies to assess
publication bias and we found marginal evidence of it
(Egger's P = 0.055, See Figure 3). We evaluated whether
reporting exactly 4 week post-TQD data influenced out-
comes and found trials reporting exactly 4 week post-TQD
data were more likely to report treatment effects (OR 2.11,
95% CI, 1.97-2.27, P =< 0.0001). These pooled trials
yielded an OR 1.82, 95% CI, 1.62-2.05, P =< 0.0001, I2 =
41.6%, 95% CI, 9.1 to 59.1%, P = 0.002). Trials reporting
on sustained abstinence at approximately 4 weeks post-
TQD yielded a similar pooled estimate (38
RCTs.[45,52,54,56,57,60,61,66,67,69,73,75,81,82,86,87
,89,91,94,98,99,103,116,124,129,131,139,142,145,149]
, n = 17,606, OR 2.24, 95% CI, 1.94-2.28, P =< 0.0001, I2
= 67.7%, 95% CI = 53.7% to 76.1%, P =< 0.0001). When
we evaluated trials assessing NRT only to placebo we
pooled 74 trials.[36-43,45-47,49-52,54-69,71,73-
82,131,84,86-91,94,95,97,98,100,103,105,106,111,114-
116,149] (total n = 25,154: 24,654) and found a pooled
estimate of 2.13 (95% CI, 1.94-2.34, P =< 0.0001, I2 =
53.6%, 95% CI = 37.6% to 64%, P =< 0.0001, this was not
dissimilar when evaluating sustained abstinence (29
RCTs.[45,52,54,56,57,60,61,66,67,69,73,75,81,82,86,87
,89,91,94,98,99,103,124,131,149], n = 14,306, OR 2.36
(95% CI, 2.04-2.73 I2 = 61.4%, 95% CI = 37.5% to 73.5%,
P =< 0.0001).
When we specifically looked at the effectiveness of NRT
gum versus all inert controls we pooled data from 41 tri-
als.[36-42,45-47,50,67,74,78,106,111,114,117-
119,121,123,124,128-132,134,137,138,141,144,146] (n
= 9,460) and found an OR of 1.76 (95% CI, 1.54-2.01, P
=< 0.0001, I2 = 38.9% (95% CI = 3.8% to 57.6%, P =
0.004). This was not dissimilar from gum versus placebo
controls (23 trials.[36-42,45-47,50,67,74,78, 106,111,
114,124,131], n = 5818, OR 1.66, 95% CI, 1.41-1.96, P =<
0.0001, I2 = 41.1% P = 95% CI = 0% to 63.2%, P = 0.01).
When we specifically examined trials assessing the effec-
tiveness of NRT cutaneous patches versus inert controls
we included data from 47 RCTs.[49,51,52,54,56,58-
60,62-66,69,71,73,77,79,82,84,86,87,89-91,95,97,100,
103,105,106,115,135,139,141-145,149] (n = 15,980)
and found a pooled estimate of 2.11 (95% CI, 1.85-2.40,
P =< 0.0001, I2 = 54.8%, 95% CI, 34.7 to 66.7%, P =<
0.0001). This was not different when examining NRT
patches versus placebo controls (38 trials
[49,51,52,54,56,58-60,62-66,69,71,73,77,79, 82,84,86,
87,89-91,95,97,100,103,105,106,115,149], n = 14,988,
OR 2.15, 95% CI, 1.86-2.48, P =< 0.0001, I2 = 59.5%, 95%
CI = 39.3 to 70.8%, P =< 0.0001).
When evaluating NRT versus controls at 6 months (96
RCTs, n = 30,422) we found a pooled estimate of OR 1.92
(95% CI, 1.73-2.14, P =< 0.0001, I2 = 64.2%, 95% CI, 54.8
to 70.8%, P =< 0.0001). This was not dissimilar whenPage 5 of 16
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Random effects meta-analysis of all NRT trials combined versus all inert controls at 4 weeksFigure 2
Random effects meta-analysis of all NRT trials combined versus all inert controls at 4 weeks. post-TQD.
Harm Reduction Journal 2009, 6:25 http://www.harmreductionjournal.com/content/6/1/25evaluating NRT as either gum (23 RCTs, n = 5818, OR
1.69, 95% CI, 1.37-2.08, P =< 0.0001, I2 = 55.9%, 95% CI,
21.8 to 71.3%, P = 0.0004) or cutaneous patch (43 RCTs,
n = 16,298, OR, 1.90, 95% CI, 1.62-2.33, I2 = 62.4%, 95%
CI, 45.5 to 72.3%, P =< 0.0001).
Bupropion
We pooled data from 31 trials.[114,142,143,149,152-
157,162-173,175-177,182-187] contributing a total n of
11,118 participants providing data at approximately 4
weeks post-TQD and found a pooled OR of 2.25 (95% CI,
1.94-2.62, P =< 0.0001, I2 = 78, 95% CI, 70-83%, P =<
0.001, See Figure 4). When we evaluated studies assessing
sustained cessation (25 randomized cohorts.[142,149,
151,152,154,155,159,160,162-166,168,170,171, 175,
176,180,182,185,187], n = 8,724) we found a pooled OR
of 1.96, 95% CI, 1.39-2.79, P = 0.0002, I2 = 89%, 95% CI,
86-92%, P =< 0.0001, See Figure 5). We were able to
explain the large heterogeneity in the analysis through
meta-regression as studies failing to report allocation con-
cealment were associated with increased effect sizes (OR
2.29, 95% CI, 2.05-2.60, P =< 0.0001), as were studies
confirming abstinence through urinary cotinine (OR
2.44, 95% CI, 2.18-2.66, P =< 0.0001), but not those uti-
lizing carbon monoxide confirmation (OR 1.30, 95% CI,
0.87-1.95, P = 0.18).
Our secondary outcomes for effectiveness also indicated
significant benefits with bupropion over controls at 6
months (OR 1.75, 95% CI, 1.54-1.97, P =< 0.0001, I2 =
32%, 95% CI, 0-53%, P =< 0.0001). This effect was con-
sistent when applying only continuous abstinence in the
6 month period (OR 1.94, 95% CI, 1.62-2.32, P =<
0.0001, I2 = 34, 95% CI, 0-62, P = 0.04).
Varenicline
When we evaluated varenicline for smoking abstinence at
approximately the last 4 weeks of treatment (4 weeks
post-TQD) compared to placebo, we pooled 9 trials.[162-
164,189-192,194,196] contributing a total n of 5,192 par-
ticipants. Our pooled estimate for abstinence at 4 weeks
post-TQD found a pooled OR of 3.16 (95% CI, 2.55-3.91,
P =< 0.0001, I2 = 53%, 95% CI, 0-76%, P = 0.02, See Fig-
ure 6). We were able to explain the heterogeneity in the
analysis through meta-regression as studies failing to
report allocation concealment were associated with
increased effect sizes (OR 3.35, 95% CI, 2.45-4.57, P =<
0.0001). Our 6 month evaluations of varenicline versus
placebo yielded similar estimates for continuous absti-
nence in the 6 month period (OR 2.17, 1.48-3.19, P =<
0.0001, I2 = 80, 95% CI, 49-90%, P =< 0.0001).
Two trials evaluated head to head comparison of vareni-
cline and bupropion and found a pooled estimate of OR
1.86 (95% CI, 1.49-2.33, P =< 0.0001) using continuous
abstinence rates at 4 weeks and, at 6 months post-TQD
(OR 1.64, 95% CI, 1.28-2.10, P =< 0.0001).[163,164]
One trial evaluated varenicline versus NRT patch (n =
757) for continuous abstinence at the last 4 weeks post-
TQD using carbon monoxide confirmation (OR 1.70,
95% CI, 1.26-2.28, P =< 0.001).[188] This same trial
reported on continuous abstinence at 6 months (24
weeks), but the difference was not significant (OR 1.29,
95% CI, 0.94-1.77, P = 0.11).
Adjusted indirect comparison (Figure 7)
We applied an adjusted indirect comparison evaluating
NRT, bupropion and varenicline on our primary endpoint
of 4 weeks post-TQD abstinence. We were unable to dis-
play a significant difference between NRT and bupropion
at 4-weeks (OR, 1.09, 95% CI, 0.93-1.31, P = 0.28). Varen-
icline was superior to both NRT (OR 1.56, 95% CI, 1.23-
1.96, P = 0.0002) and bupropion at post-TQD (OR 1.40,
95% CI, 1.08-1.85, P = 0.01).
Discussion
This study confirms the short-term effectiveness of all
three smoking interventions compared to placebo. Our
findings stand in line with outcomes evaluated over a
longer period, up to one year, of these same interven-
tions.[9,10] This finding should be of interest to clini-
cians, policy-makers and patients. As interventions to
assist in smoking cessation are increasingly available, the
combination of these interventions, along with socio-
behavioural interventions, should be a research prior-
ity.[8]
The definition of smoking abstinence and relapse are var-
iable across studies. The most common time periods of
Funnel plot evaluating publication bias in NRT versus control eve t rates at 4 weeks post-TQDigure 3
Funnel plot evaluating publication bias in NRT versus 
control event rates at 4 weeks post-TQD.
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Harm Reduction Journal 2009, 6:25 http://www.harmreductionjournal.com/content/6/1/25smoking cessation required to be considered abstinent are
24 hours, 7 days and 30 days. Relapse is defined by the
National Heart, Lung and Blood Institute as having
smoked at least a puff for 7 days after having quit. Seventy
five to 80 percent of smokers relapse within the first 6
months. Relapse rates continue to remain high from 6 to
12 months (7 to 35% of those abstinent at 6 months).
Relapse occurs at a lower rate following one year of cessa-
tion.[4] The National Center for Health Education Code
of Practice and Standards for the Evaluation of Group
Smoking Cessation Programs recommends at least one
year of follow-up before determining if patients have quit
smoking.[4] The National Institute for Clinical Excellence
(UK) Guidelines require the reporting of short-term absti-
nence rates. Further, immediate abstinence of smoking
following a major cardiovascular event has major benefits
in preventing secondary events.[197] We recognize that
multiple short-term abstinence attempts followed by
relapses may be associated with long term smoking use,
an issue that is increasingly complex to manage from a
clinical and public health perspective.[198] However, our
findings are consistent with the longer term evaluations
and indicate that sustained abstinence is possible in the
clinical trial setting. Furthermore there are some physio-
logical and health advantages to short-term abstinence.
For example, individuals with cardiovascular events can
immediately benefit from smoking discontinuation
because of improvements in several physiological varia-
bles including reduced myocardial oxygen demand,
improved myocardial oxygen supply, reduced activation
of the sympathetic system, reduced risk of arrhythmias
and reduced acute thrombosis risk. These benefits could
be particularly critical in the peri-event period when
patients are at increased risk of complications or repeat
events. Thus even if relapse occurs at a later stage, absti-
nence around the time of an event could prove beneficial.
When we previously evaluated varenicline to NRT and
bupropion, we had data from only 4 trials.[9] This evalu-
ation found that the addition of 7 trials continues to dem-
onstrate elevated varenicline effects compared to NRT and
bupropion. Further community effectiveness interven-
tions will be required to ensure generalizability.
There are several strengths and limitations to consider
when interpreting our analysis. Strengths of this review
include the comprehensive search strategy that improved
the likelihood of identifying all relevant studies. Dupli-
cate extraction of data reduced the potential for bias in
this component of the synthesis process. By limiting this
review to randomized trials we ensured that the included
studies would have reduced likelihood of systematic error
and therefore have high internal validity. Our use of meta-
regression to identify sources of heterogeneity in the
meta-analyses is a strength and demonstrated that several
of the a priori chosen covariates were predictors of hetero-
geneity. To reduce patient-reporting bias, we included
only studies that chemically confirmed the cessation of
smoking at the specific time-points- this has been a weak-
ness in previous reviews.[23]
Limitations of this meta-analysis include the potential for
publication bias, in particular the possibility that small
negative studies would not be published. Publication bias
on short-term effects is likely due to both author-initiated
bias and journal-initiated bias against short-term evalua-
tions. We included only published trials so it is possible
that other trials have been conducted and never pub-
lished. However, it is unlikely that the presence of these
studies would have altered the findings of our analysis
given the large number of studies included and the con-
sistency with the longer-term evaluations (both 6 months
and one year).[9,10] We limited our search to English lan-
guage databases (although we would include non-English
articles if identified) so the possibility of quality studies in
other languages does exist. We used both direct and indi-
rect comparisons to evaluate the relative effectiveness of
agents. Head-to-head trials provide the strongest infer-
ences regarding intervention superiority.[34] In the pres-
ence of existing head-to-head trials of varenicline versus
NRT.[188] and bupropion,.[163,164] it is arguable
whether indirect comparisons are required.[199] In this
case, the results were consistent. We used the indirect
comparison method proposed by Bucher et al., that
respects the principle of randomization between tri-
als.[200] Other strategies we have previously
applied,.[201] including mixed treatment comparisons,
offer similar benefits.[199]
Random effects meta-analysis of varenicline versus placebo at 4 weeks post-TQDFigure 6
Random effects meta-analysis of varenicline versus 
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In conclusion, our review demonstrates clear efficacy of
smoking cessation pharmacotherapies in the short term
and provides similar estimates of efficacy as longer term
evaluations.[9,10] Given the benefits of smoking absti-
nence in both primary and secondary prevention of major
morbidities, the use of these therapies in patients with
active smoking related disease warrants further study.[15]
Future research to evaluate the efficacy and safety of these
interventions in combination and in patients with
advanced diseases is warranted.
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